Get the app
US › Healthcare

Omnicell Inc (OMCL)

US · Healthcare · Health Information Services

$37.34-1.81%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$307.9M
Revenue YoY
-0.9%
Net profit
$11.0M
Profit YoY
+102.2%
EPS
$0.36
EPS estimate
$0.24
Net margin
3.6%

EPS came in at 0.36 against a street estimate of 0.24 — a beat of 50.0%.

Key statistics

Market cap
$1.68B
P/E
43.9
Forward P/E
29.5
P/B
1.30
Book value
$28.70
EPS (TTM)
$0.84
52-week high
$55.00
52-week low
$31.75
50-day MA
$34.58
200-day MA
$39.10
Beta
0.99

Analyst view

Analysts rate Omnicell Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $57.86.

From the latest earnings call · 2026-10-29

CONFIDENT Omnicell beat Q3 revenue and EBITDA guidance, raised full-year profitability targets, and reported stronger pipeline momentum, though bookings timing and customer decisions remain uncertain. Q3 FY26 No geographic revenue breakdown was discussed. Analysts focused on bookings timing, leasing economics, pipeline conversion and margin progression. Management emphasized customer decision cycles, competitive deal variability and disciplined cost control. 2026-10-29…

Full summary in the app.

Shareholding

Insiders
2.15%
Institutions
109.11%

Largest institutional holders

FundStake
BlackRock Inc16.53%
Vanguard Portfolio Management, LLC6.91%
Wellington Management Company LLP5.92%
Dimensional Fund Advisors, Inc.5.38%
State Street Corp4.57%
Vanguard Capital Management, LLC4.32%
Millennium Management LLC3.80%
Delaware Management Holdings Inc3.52%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
HEADLINE NUMBERS • Nine-month 2026 revenue was $929,939, up from $870,861 in nine-month 2025. • Nine-month 2026 net income was $46,691, compared wit
2026-11-04
Results announced · Q4 2026
HEADLINE NUMBERS • Q3 2026 revenue was $308 million, down $3 million, or 1%, from Q3 2025. • GAAP net income was $11 million, or $0.24 per diluted s
2026-10-29
Quarterly report · Q2 2026
OMNICELL, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (6M 2026): $622,088 thousand ($622.1 million), up from $560,230 thousand in
2026-08-05
Results announced · Q3 2026
OMNICELL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: July 30, 2026 for quarter ended June 30, 2026 (Q2 2026) • Company: Omnicell, Inc.
2026-07-30
Board / officer change · Q2 2026
OMNICELL, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Nnamdi Njoku appointed President of Omnicell, effective July 1, 2026, while retain
2026-07-01
Board / officer change · Q2 2026
OMNICELL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • 1,600,000 additional shares authorized under equity incentiv
2026-05-26
Quarterly report · Q1 2026
OMNICELL, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Q1 2026 Total Revenues: $309.9 million (up from $269.7 million in Q1 2025, +14.9% grow
2026-05-06
Results announced · Q2 2026
OMNICELL, INC. - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $310 million, up $40 million or 15% year-over-year from $270 m
2026-04-28

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Omnicell Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.